

#3

PATENT
ATTORNEY DOCKET NO. 50093/014001

Certificate of Mailing: Date of Deposit: February 8, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.

Mary Jane DiPalma

Printed name of person mailing correspondence

Mary Jane DiPalma

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony Giordano et al.

Art Unit: 1643

Serial No.: 09/437,458

Examiner:

Filed: November 10, 1999

Title: NUCLEIC ACID SEQUENCES AND METHODS FOR IDENTIFYING
COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN
INTERACTIONS AND mRNA FUNCTIONALITY

Assistant Commissioner of Patents
Washington, D.C. 20231

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

In reply to the Notice To Comply mailed December 9, 1999, Applicant submits the following:

☒ An initial paper copy of the sequence listing to be inserted at the end of the application.

☒ An initial copy of the sequence listing in computer readable form.

☒ A statement that the contents of the paper and computer readable copies are the same and contain no new matter.

Respectfully submitted,

Date:


February 8, 2010

Kristina Bieker-Brady
Kristina Bieker-Brady, Ph.D.

Reg. No. 39,109

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\\Ceserver\documents\50093\50093.014001 Reply to NTComply.wpd



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/437,458 11/10/99 GIORDANO

A 50093/261400

014001

KRISTINA BIEKER-BRADY PHD
CLARK AND ELBING LLP
176 FEDERAL STREET
BOSTON MA 02110

0262/1209

NOT ASSIGNED

1643

DATE MAILED:

12/09/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER: _____

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing";
- ☒ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:


- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For PatentIn software help, call (703) 308-6856.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

BEST AVAILABLE COPY



PATENT
ATTORNEY DOCKET NO. 50093/014001

Certificate of Mailing: Date of Deposit: February 8, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.

Mary Jane DiPalma

Printed name of person mailing correspondence

Mary Jane DiPalma
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony Giordano et al.

Art Unit: 1643

Serial No.: 09/437,458

Examiner:

Filed: November 10, 1999

Title: NUCLEIC ACID SEQUENCES AND METHODS FOR IDENTIFYING
COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN
INTERACTIONS AND mRNA FUNCTIONALITY

Assistant Commissioner of Patents
Washington, D.C. 20231

STATEMENT UNDER 37 CFR §1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 CFR §§1.821 through 1.825 and consisting of 5 pages.

As required by 37 CFR 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 CFR §1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 CFR 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 CFR §1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.


As required by 37 CFR §1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

February 8, 2000


Kristina Bleker-Brady, Ph.D.
(Reg. No. 39,109)

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045